Basilea Pharmaceutica AG announced the completion of patient enrolment into the phase 3 ERADICATE study. This study is investigating ceftobiprole in the treatment of patients with complicated bloodstream infections caused by Staphylococcus aureus, also referred to as Staphylococcus aureus bacteremia (SAB). ERADICATE reached its target enrolment of 390 patients. ERADICATE is the second of two phase 3 studies necessary for a regulatory filing of ceftobiprole in the U.S. The first study, TARGET, in patients with acute bacterial skin and skin structure infections (ABSSSI) reported positive results in 2019. If the results of the ERADICATE study are also positive, a New Drug Application will be submitted to the U.S. Food and Drug Administration (FDA). The U.S. is the larger potential market for ceftobiprole, considering the high incidence of MRSA (methicillin-resistant Staphylococcus aureus) infections in the U.S. Basilea's ceftobiprole phase 3 program is funded in part (up to USD 134.2 million, which is approximately 70% of the total potential program costs) with federal funds from the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C.